Dandrit strengthens its European Patent base. This company has potential of surpassing rival Dendreon in the field of Cancer Vaccine Astonishing – but true….
Dandrit A/s is through merger of cash-rich DKTI A/S securing a financial platform for expansion and a platform on the Copenhagen Stock Exchange. Ongoing talks – that were first publicized late 2011 have now resulted in a proposed merger – please see details here.
DanDrit Biotech A/S is a clinical-stage company developing the world’s first vaccine against colorectal cancer. DanDrit technology is based on development of dendritic cell vaccines. Like Dendreon – DanDrit’ base their development on a single lead compound, (in Dandrit’s case called) MelCancerVac, an allogenic dendritic cell vaccine. Dandrit has completed two Phase II clinical trials for the treatment of advanced colorectal cancer and non-small cell lung cancer (NSCLC). DanDrit now takes MCV into a randomized comparative Phase IIb / III clinical trial in advanced colorectal cancer.
Presently the vaccine can be used for compassionate use (Singapore)
